Incyte's new CEO outlines growth plan as Jakafi patent cliff nears
I'm PortAI, I can summarize articles.
Incyte Corp's new CEO, Bill Meury, has unveiled a growth strategy focused on drug development and capital allocation as the company approaches the patent expiration of its leading drug, Jakafi. Following his first earnings call, Incyte's shares rose nearly 8%. The company raised its 2025 Jakafi sales forecast to $3 billion-$3.05 billion, with Q2 sales reaching $763.8 million. Incyte is also banking on its vitiligo treatment, Opzelura, which saw a 35% sales increase. Meury remains open to strategic deals to enhance growth.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments